Genus plc (GENSY)
OTCMKTS · Delayed Price · Currency is USD
42.84
+0.37 (0.87%)
At close: Feb 11, 2026
Genus Revenue
In the fiscal year ending June 30, 2025, Genus had annual revenue of 672.80M GBP with 0.60% growth. Genus had revenue of 336.40M in the half year ending June 30, 2025, a decrease of -0.91%.
Revenue
672.80M GBP
Revenue Growth
+0.60%
P/S Ratio
3.05
Revenue / Employee
210.91K GBP
Employees
3,190
Market Cap
2.81B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 672.80M | 4.00M | 0.60% |
| Jun 30, 2024 | 668.80M | -20.90M | -3.03% |
| Jun 30, 2023 | 689.70M | 96.30M | 16.23% |
| Jun 30, 2022 | 593.40M | 19.10M | 3.33% |
| Jun 30, 2021 | 574.30M | 22.90M | 4.15% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |